Concurrent weekly cisplatin vs triweekly cisplatin with radiotherapy for treatment of locally advanced cervical cancer

Dr Ajit Kumar; Dr Aradhna Tripathi

Volume : IX, Issue : II, February - 2020

Concurrent weekly cisplatin vs triweekly cisplatin with radiotherapy for treatment of locally advanced cervical cancer

Dr Ajit Kumar, Dr Aradhna Tripathi

Abstract :

Introduction- The present study was conducted to assess the efficacy and toxicity profile of concurrent weekly cisplatin dosing as compared to 3 weekly cisplatin with radiotherapy in patients of cervical cancer and also to evaluate the compliance among them. Methodology- This was prospective randomized comparative study at tertiary centreon patients of locally advanced cervical cancer. Patients were randomly divided into 2 groups and patients of group 1 received EBRT with weekly cisplatin whereas patients of group 2 received EBRT with 3 weekly cisplatin. All the patients were followed up for assessment of compliance, acute toxicities and treatment response. Results- The study included 80 patients which were randomized into 2 groups. The population in two groups was comparable in baseline characteristics. No statistically significant difference in occurrence of acute toxicities between the participants of two groups was observed (p>0.05). Clinically, complete response was noted in 82.5% and 90% patients in group 1 and group 2 respectively. However the observed difference in response was not statistically significant (p>0.05). Conclusion-The present study documented similar response and toxicity profile of both the regimens and thus concurrent weekly or 3 weekly cisplatin along with radiotherapy can be used with equal effectiveness in the treatment of cervical cancer.